| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/NM0697-651 |
| P698 | PubMed publication ID | 9176492 |
| P50 | author | Robert Gallo | Q469904 |
| Susan Zolla-Pazner | Q30590702 | ||
| Marjorie Robert-Guroff | Q30651738 | ||
| P2093 | author name string | Mizutani S | |
| Davis A | |||
| Reitz MS Jr | |||
| Sinangil F | |||
| Murthy SC | |||
| Markham PD | |||
| Wade M | |||
| Arthur LO | |||
| Chanda PK | |||
| Hung PP | |||
| Lubeck MD | |||
| Eichberg J | |||
| Nigida SM Jr | |||
| Kalyan N | |||
| Steimer K | |||
| Alipanah S | |||
| Myagkikh M | |||
| Aldrich K | |||
| Natuk R | |||
| P2860 | cites work | A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp160 | Q28279759 |
| NASBATM isothermal enzymatic in vitro nucleic acid amplification optimized for the diagnosis of HIV-1 infection | Q28285678 | ||
| An immunodominant epitope of the human immunodeficiency virus envelope glycoprotein gp160 recognized by class I major histocompatibility complex molecule-restricted murine cytotoxic T lymphocytes. | Q33570776 | ||
| Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120 | Q33632668 | ||
| Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. | Q34214455 | ||
| Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus | Q34301871 | ||
| Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide | Q34632476 | ||
| Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus. | Q35839114 | ||
| Vaccine-induced protection of chimpanzees against infection by a heterologous human immunodeficiency virus type 1. | Q35848078 | ||
| Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain | Q35872988 | ||
| Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees | Q36811962 | ||
| Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120 | Q36832017 | ||
| Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques | Q36952733 | ||
| Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus | Q37375345 | ||
| Effect of intron A from human cytomegalovirus (Towne) immediate-early gene on heterologous expression in mammalian cells | Q38334274 | ||
| Amplification and sequence analysis of DNA flanking integrated proviruses by a simple two-step polymerase chain reaction method. | Q40048383 | ||
| Titration of a vaccine stock preparation of human immunodeficiency virus type 1SF2 in cultured lymphocytes and in chimpanzees | Q40926483 | ||
| Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies | Q44683552 | ||
| Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells | Q44761396 | ||
| Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. | Q45772548 | ||
| Immune response of chimpanzees after immunization with the inactivated whole immunodeficiency virus (HIV-1), three different adjuvants and challenge | Q45774090 | ||
| Immunogenicity of recombinant human adenovirus-human immunodeficiency virus vaccines in chimpanzees | Q45776493 | ||
| HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees | Q45781750 | ||
| Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration | Q45783638 | ||
| High level expression of the envelope glycoproteins of the human immunodeficiency virus type I in presence of rev gene using helper-independent adenovirus type 7 recombinants | Q45850377 | ||
| Nonaffinity purification of recombinant gp120 for use in AIDS vaccine development | Q46108397 | ||
| Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody | Q46352552 | ||
| Resistance of chimpanzees immunized with recombinant gp120SF2 to challenge by HIV-1SF2. | Q46820907 | ||
| Induction of HIV‐1 envelope (gp120)‐specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell‐derived gp120 is enhanced by enzymatic removal of N‐linked glycans | Q52536298 | ||
| Effect of immunization with a vaccinia-HIV env recombinant on HIV infection of chimpanzees | Q52849021 | ||
| Anti-cell antibody in macaques | Q59098168 | ||
| Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines | Q67972576 | ||
| A resting cell assay for improved detection of antibody-mediated neutralization of HIV type 1 primary isolates | Q71185106 | ||
| Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques | Q71802849 | ||
| HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques | Q71803147 | ||
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | immunization | Q1415366 |
| P304 | page(s) | 651-658 | |
| P577 | publication date | 1997-06-01 | |
| P1433 | published in | Nature medicine | Q1633234 |
| P1476 | title | Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization | |
| P478 | volume | 3 |
| Q33603494 | A human immunodeficiency virus prime-boost immunization regimen in humans induces antibodies that show interclade cross-reactivity and neutralize several X4-, R5-, and dualtropic clade B and C primary isolates |
| Q44035641 | A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees |
| Q33743663 | AIDS and HIV vaccines |
| Q33534217 | AIDS vaccine development: let a thousand flowers bloom |
| Q64379647 | Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols |
| Q36625165 | Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy |
| Q36288930 | Adenovirus as vehicle for anticancer genetic immunotherapy |
| Q34070158 | Adenovirus vectors for human gene therapy |
| Q34353523 | Adenoviruses as vaccine vectors |
| Q34992681 | Amplified and persistent immune responses generated by single-cycle replicating adenovirus vaccines |
| Q35898573 | An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge |
| Q36667821 | Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDS |
| Q33877513 | Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant |
| Q35743279 | Approaches to enhance the efficacy of DNA vaccines |
| Q34050712 | Assessment of HIV vaccine development: past, present, and future |
| Q36071414 | Beyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector. |
| Q30976921 | Boosting of SIV-specific immune responses in rhesus macaques by repeated administration of Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinants |
| Q40345527 | Chimpanzee-origin adenovirus vectors as vaccine carriers. |
| Q45753183 | Comparative Analysis of Humoral Immune Responses to HIV Type 1 Envelope Glycoproteins in Mice Immunized with a DNA Vaccine, Recombinant Semliki Forest Virus RNA, or Recombinant Semliki Forest Virus Particles |
| Q34616275 | Comparative analysis of SIV-specific cellular immune responses induced by different vaccine platforms in rhesus macaques |
| Q45399692 | Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251). |
| Q36981370 | Comparison of systemic and mucosal immunization with helper-dependent adenoviruses for vaccination against mucosal challenge with SHIV. |
| Q40957597 | Construction and characterization of recombinant VLPs and Semliki-Forest virus live vectors for comparative evaluation in the SHIV monkey model |
| Q33872445 | Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains |
| Q37033311 | Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques |
| Q34502108 | Current progress in the development of a prophylactic vaccine for HIV-1 |
| Q34039310 | Delivery systems and adjuvants for vaccination against HIV. |
| Q40669254 | Development of an Ad7 cosmid system and generation of an Ad7deltaE1deltaE3HIV(MN) env/rev recombinant virus |
| Q64377680 | Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses |
| Q34067641 | Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses |
| Q35021632 | Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors |
| Q28732438 | Elicitation of neutralizing antibodies directed against CD4-induced epitope(s) using a CD4 mimetic cross-linked to a HIV-1 envelope glycoprotein |
| Q61641083 | Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag |
| Q35883639 | Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission |
| Q33649657 | Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251. |
| Q77198761 | Four novel cytotoxic T-lymphocyte epitopes in the highly conserved major homology region of HIV-1 Gag, restricted through B*4402, B*1801, A*2601, B*70 (B*1509) |
| Q89552900 | Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope |
| Q34485178 | Genomic Analysis Reveals Pre- and Postchallenge Differences in a Rhesus Macaque AIDS Vaccine Trial: Insights into Mechanisms of Vaccine Efficacy |
| Q35166836 | HIV vaccines 1983-2003. |
| Q35032794 | HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques |
| Q30381447 | HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development. |
| Q34876150 | HIV-1 vaccines: the search continues |
| Q28394899 | Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials |
| Q33915690 | Humoral immunity induced by mucosal and/or systemic SIV-specific vaccine platforms suggests novel combinatorial approaches for enhancing responses |
| Q36209205 | INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. |
| Q37123522 | Identification of a Suppressor Mutation That Improves the Yields of Hexon-Modified Adenovirus Vectors |
| Q35155380 | Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen |
| Q34069214 | Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. |
| Q33639684 | Limited breadth of the protective immunity elicited by simian immunodeficiency virus SIVmne gp160 vaccines in a combination immunization regimen |
| Q34229968 | Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses |
| Q35049812 | Monkeying around with HIV vaccines: using rhesus macaques to define 'gatekeepers' for clinical trials |
| Q34075698 | Mucosal delivery of human papillomavirus pseudovirus-encapsidated plasmids improves the potency of DNA vaccination |
| Q35838661 | Mucosal immunity: overcoming the barrier for induction of proximal responses. |
| Q36827361 | Mucosal priming with a replicating-vaccinia virus-based vaccine elicits protective immunity to simian immunodeficiency virus challenge in rhesus monkeys |
| Q33966586 | Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques |
| Q46698850 | N-fragment of edema factor as a candidate antigen for immunization against anthrax |
| Q61641127 | NOVEL STRATEGIES TOWARD THE DEVELOPMENT OF AN EFFECTIVE VACCINE TO PREVENT HUMAN IMMUNODEFICIENCY VIRUS INFECTION OR ACQUIRED IMMUNODEFICIENCY VIRUS* |
| Q36603515 | Neutralizing antibodies to HIV-1 induced by immunization. |
| Q34510525 | Nucleic acid vaccines: tasks and tactics. |
| Q40481125 | Oral delivery of replication-competent adenovirus vectors is well tolerated by SIV- and SHIV-infected rhesus macaques. |
| Q30371162 | Oral priming with replicating adenovirus serotype 4 followed by subunit H5N1 vaccine boost promotes antibody affinity maturation and expands H5N1 cross-clade neutralization. |
| Q43456332 | Phase II controlled trial of post-exposure immunization with recombinant gp160 versus antiretroviral therapy in asymptomatic HIV-1-infected adults |
| Q35182076 | Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. |
| Q64380272 | Presentation of SIVgag to monkey T cells using dendritic cells transfected with a recombinant adenovirus |
| Q36954239 | Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting |
| Q36143517 | Protective immunity against botulism provided by a single dose vaccination with an adenovirus-vectored vaccine |
| Q35805265 | Protective immunity against tularemia provided by an adenovirus-vectored vaccine expressing Tul4 of Francisella tularensis |
| Q34416398 | Rational development of prophylactic HIV vaccines based on structural and regulatory proteins |
| Q35940685 | Replicating Adenovirus-Simian Immunodeficiency Virus (SIV) Vectors Efficiently Prime SIV-Specific Systemic and Mucosal Immune Responses by Targeting Myeloid Dendritic Cells and Persisting in Rectal Macrophages, Regardless of Immunization Route |
| Q64376800 | Replicating adenovirus HIV/SIV recombinant priming alone or in combination with a gp140 protein boost results in significant control of viremia following a SHIV89.6P challenge in Mamu-A*01 negative rhesus macaques |
| Q56993265 | Replicating adenovirus vector prime/protein boost strategies for HIV vaccine development |
| Q35867976 | Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac2 |
| Q33911986 | Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies |
| Q33819493 | Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques |
| Q47282517 | Single-cycle adenovirus vectors in the current vaccine landscape |
| Q34096530 | Soluble HIV-1 Env trimers in adjuvant elicit potent and diverse functional B cell responses in primates |
| Q35141486 | Strong viremia control in vaccinated macaques does not prevent gradual Th17 cell loss from central memory |
| Q37297052 | Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge |
| Q33786386 | Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. |
| Q34810713 | Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia |
| Q34332708 | Vaccines for the prevention of HIV-1 disease |
| Q33932258 | Viable adenovirus vaccine prototypes: high-level production of a papillomavirus capsid antigen from the major late transcriptional unit |
| Q33555112 | beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques |
Search more.